Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to asses the pharmacokinetics and safety of dexlansoprazole
modified release (MR), once daily (QD), in adolescent subjects (age 12-17 years old) with
Symptomatic Gastroesophageal Reflux Disease.